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Abstract
Huntington disease (HD; OMIM 143100), a progressive neurodegenerative disorder, is
caused by an expanded trinucleotide CAG (polyQ) motif in the HTT gene. Cardiovascular
symptoms, often present in early stage HD patients, are, in general, ascribed to dysautono-
mia. However, cardio-specific expression of polyQ peptides caused pathological response
in murine models, suggesting the presence of a nervous system-independent heart pheno-
type in HD patients. A positive correlation between the CAG repeat size and severity of
symptoms observed in HD patients has also been observed in in vitro HD cellular models.
Here, we test the suitability of human embryonic stem cell (hESC) lines carrying HD-specific
mutation as in vitromodels for understanding molecular mechanisms of cardiac pathology
seen in HD patients. We have differentiated three HD-hESC lines into cardiomyocytes and
investigated CAG stability up to 60 days after starting differentiation. To assess CAG stabili-
ty in other tissues, the lines were also subjected to in vivo differentiation into teratomas for
10 weeks. Neither directed differentiation into cardiomyocytes in vitro nor in vivo differentia-
tion into teratomas, rich in immature neuronal tissue, led to an increase in the number of
CAG repeats. Although the CAG stability might be cell line-dependent, induced pluripotent
stem cells generated from patients with larger numbers of CAG repeats could have an ad-
vantage as a research tool for understanding cardiac symptoms of HD patients.
PLOS ONE | DOI:10.1371/journal.pone.0126860 May 20, 2015 1 / 14
OPEN ACCESS
Citation: Jacquet L, Neueder A, Földes G,
Karagiannis P, Hobbs C, Jolinon N, et al. (2015)
Three Huntington’s Disease Specific Mutation-
Carrying Human Embryonic Stem Cell Lines Have
Stable Number of CAG Repeats upon In Vitro
Differentiation into Cardiomyocytes. PLoS ONE 10
(5): e0126860. doi:10.1371/journal.pone.0126860
Academic Editor: Majlinda Lako, University of
Newcastle upon Tyne, UNITED KINGDOM
Received: October 12, 2014
Accepted: April 8, 2015
Published: May 20, 2015
Copyright: © 2015 Jacquet et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All data are included in
the body of the manuscript.
Funding: This work was supported by the UK
Medical Research Council (MRC) grants G0701172
and G0801061. L.J. had MRC studentship.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Huntington’s disease (HD; OMIM 143100) is an autosomal, dominantly inherited progressive
neurodegenerative disorder usually with a late onset. It is caused by an expanded polymorphic
polyglutamine (polyQ) trinucleotide (CAG) motif in the first exon of the HTT gene. HTT en-
codes huntingtin (HTT), a large 348 kD protein ubiquitously expressed, with highest levels
found in the brain and testis [1–4]. HTT endogenous function is still not completely under-
stood as it has very little homology to other known proteins [1].
In healthy individuals, the CAG repeat number ranges from 11 to 34 while numbers greater
than 36 are causative of HD. The number of repeats generally determines age of disease onset
[1, 5, 6]. Individuals with over 55 CAG repeats tend to develop Juvenile Huntington’s Disease
(JHD), a more severe form, with slightly different clinical manifestations that develop in their
youth instead of in their third to fifth decade. HD patients bearing homozygous mutations do
not automatically have a lower age of onset, but do have a more severe phenotype and disease
progression.6 The mutation shows anticipation, with both decreases and increases in repeat
length occurring upon parent to offspring transmission [1, 7]. Instability of the CAG repeat
length has also been reported in somatic tissues, with the largest expansion being observed in
the brain [8, 9]. Cognitive decline, irritability and depression are often the first signs of disease,
preceding clinical diagnosis and the development of motor symptoms [10]. Uncontrollable
movements, difficulty in speech and swallowing lead to progressive physical deterioration,
total dependency and need for full nursing care. Death is usually the result of secondary illness.
HTT is ubiquitously expressed. Neurodegeneration is the main HD phenotype, however,
non-central nervous system HD-associated pathologies have also been reported [11–13]. Or-
thostatic hypotension, tachycardia, impaired modulation of cardiovascular tone and attenuated
heart rate responses to stress, often present in early stage HD patients, have been ascribed to
dysfunction of the autonomous nervous system [14–19]. Cardiac pathology, including atrophy,
has been, however, described in HD murine models [13, 20–22]. In addition, cardiomyocyte-
autonomous expression of 83 polyQ peptide in mouse model led to reduced cardiac function
and dilatation by 5 months followed by death by 8 months. On the contrary, a 9-fold higher ex-
pression of 19 polyQ peptide in control animals had no effect on murine cardiac function or
lifespan [23]. Taken together, the data from animal models suggest that the cardiac phenotype
seen in HD patients is not exclusively a result of dysautonomia; and that the expression of mu-
tant HTT in cardiomyocytes may also be cardiotoxic.
Human pluripotent stem cells, bearing the endogenousHTTmutation, can be differentiated
into multiple cell lineages and kept in culture ad infinitum, circumventing the limitations asso-
ciated with primary cell culture or immortalized cell lines with exogenously expressed mutant
HTT. The aim of this study was to test the stability of CAG repeats in cardyomyocytes differen-
tiated in vitro from three HD-hESC lines [24], KCL027, KCL028 and KCL036.
Methods
2.1. hESC derivation, culture, expression of pluripotency markers and in
vivo differentiation (teratoma)
HD-hESCs were derived from fresh embryos diagnosed with HD following Preimplantation
Genetic Diagnosis (PGD). The work was done under the Human Fertilisation and Embryology
Authority (HFEA; research license number R0133) and local ethical approval (UK National
Health Service Research Ethics Committee Reference 06/Q0702/90) following the written in-
formed consent from the donors. All hESC lines have been approved for deposit in the UK
Stem Cell Bank by the Medical Research Council’s Steering Committee. All the lines are also
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listed in the NIH hESC Registry as ethically derived and eligible for use in NIH funded re-
search. The methods describing hESC derivation, culture, expression of pluripotency markers
and in vivo differentiation are reported in detail previously [25, 26].
2.2. Genotyping
Genotyping was performed as previously described [25]. Briefly, DNA was extracted from
hESC cultures using a Chemagen DNA extraction robot, quantified using a Nanodrop spectro-
photometer, and amplified using two multiplexes, one of 17 PCR primer pairs for markers on
chromosomes 13, 18 and 21, and one of 14 primer pairs for markers on the X and Y chromo-
somes. PCR products, separated on an ABI3100 capillary genetic analyser, were analyzed using
ABI Genotyper software. Allele sizes represent a unique fingerprint of each cell line.
2.3. Array comparative genomic hybridization (CGH)
Array CGH was performed as previously described [25]. Briefly, 1 μg DNA was labelled using a
CGH labelling kit (Enzo Life Sciences, USA) and purified post-labelling using QIAquick PCR
Purification Kit (Qiagen, USA). Labelling efficiency and yield was assessed by spectrophotome-
try (Nanodrop, USA). We used an Agilent (USA) 4 × 44 K platform with either Wessex NGRL
design 017457 or design 028469. The data were processed using Feature Extraction and DNA
Analytics software packages (Agilent, USA); 95% of array data was required to pass QC. For
aberration calling, we used ADM-2 algorithm at threshold 6 (with a 3 probe sliding window
providing a mean detection interval of 200 kb).
2.4. Cardiac differentiation
Directed cardiac differentiation was based on the work published by Laflamme et al [27]. Brief-
ly, undifferentiated hESCs, maintained on Matrigel (BD) in Nutristem (Stemgent), were disso-
ciated into a single-cell suspension by a 3–5 min incubation with accutase (STEMCELL
Technologies). Cells were then centrifuged, resuspended, counted and seeded in Nutristem
onto growth factor reduced Matrigel coated 24-well plates at a density of 2 x 105 cells/cm2, with
the addition of 10 μMY-27632 (Source Bioscience) to support cell survival and attachment.
This marked Day -5 of the differentiation protocol. Until Day 0, cells were fed daily with 2
ml/well of Nutristem. At Day 0, cardiac differentiation was induced by feeding the cells with
0.5 ml/well Roswell Park Memorial Institute medium (RPMI)-B27 medium (Invitrogen) sup-
plemented with 100 ng/ml of human recombinant Activin A (Miltenyi). The following day, the
medium was replaced by 1.5 ml/well RPMI-B27 supplemented with 10 ng/ml human recombi-
nant BMP4 (Miltenyi) and left unchanged for four days. The medium was then exchanged for
unsupplemented RPMI-B27 every two days for up to 60 days.
2.5. Reverse transcription (RT)-PCR and quantitative (q) PCR
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN) following the manufacturer’s
instructions. A 20 min DNAse I (27 Kunitz units final) (Qiagen) treatment step at room tem-
perature was included to eliminate potential genomic DNA contamination. cDNA was gener-
ated by reverse-transcription of total RNA (500 ng) in a 20-μl reaction using the Precision
nanoScript Reverse Transcription kit (PrimerDesign) following the manufacturer’s instruction.
The qPCR reaction consisted of 5 μL of cDNA diluted 1:10 in water, 10 μl of Precision 2X
qPCRMastermix (PrimerDesign) and 300 μM final of each primer for a final volume of 20 μl.
qPCR cycling conditions were as follow: 1 cycle 95°C for 10 min; 40 cycles 95°C for 15 s, 61°C
for 30 sec followed by melt curve acquisition from 59°C to 95°C with 0.5°C increment. To select
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the best housekeeping gene, we tested a panel of 12 different housekeeping genes on undiffer-
entiated hESCs and hESC-derived cardiomyocytes. GeNorm analysis was then performed via
the qbasePLUS software in order to determine the two most stable ones, which were EIF4A2 and
SDHA. The POUF51 (also known as OCT4), NANOG, TNNT2, EIF4A2 and SDHA primers
were designed by PrimerDesign Ltd and theHTT primers were designed using the Primer3
website (http://frodo.wi.mit.edu/). Primers are listed in S1 Table. All samples were analyzed in
triplicate, Ct values were determined, and the expression was calculated by the 2-ΔΔCt method.
EIF4A2 and SDHA were used for internal normalisation (S2 Table).
2.6. Isolation of DNA from formalin-fixed paraffin embedded (FFPE)
teratoma tissue
Eight serial 6-μm sections from each paraffin block with embedded teratoma tissue were pro-
cessed for the analysis. The first and the last section were stained with hematoxylin and eosin
(H&E) and the tissue types spanning both sections were determined. We purified DNA from
the remaining six sections and determined number of CAG repeats using human-specific
primers. The wild-type (WT) allele was used as an internal control.
Isolation of DNA from FFPE tissue was adapted from Campos and Gilbert [29]. The FFPE
tissue samples were digested in 500 μl alkali digestion buffer (0.1 M NaOH with 1% SDS, pH
12) for 40 min at 100°C. After a 5 min of cooling down period, 500 μl of 25:24:1 phenol:chloro-
form:isoamyl alcohol was added to the samples, followed by a 5 min agitation at room temper-
ature and 5 min centrifugation at 10,000 x g. The upper aqueous layer was then removed and
added to a new tube containing 500 μl choloroform. A second agitation and centrifugation step
was performed before adding the aqueous layer to 1 volume of isopropanol and 0.1 volume of
3 M sodium acetate pH 5. The samples were then centrifuged 30 min at 10,000 x g. Liquid was
then decanted and the DNA pellet washed twice with 1 ml 85% ethanol. After ethanol decanta-
tion, the DNA pellet was allowed to dry before resuspension in TE buffer.
2.7. CAG repeats
Preimplantation genetic haplotyping (PGH) for HD was performed as described previously
[24, 25]. CAG repeat size determination of the cell (wells with predominantly beating cells)
and tissue samples (teratoma sections) was performed by PCR as published [30]. Briefly,
5–50 ng DNA amplification was performed in 10 μl reactions containing: 0.2 mM dNTPs, 10%
DMSO, AM buffer (67 mM Tris–HCl pH 8.8; 16.6 mM (NH4)SO4; 2 mMMgCl2; 0.17 mg/ml
BSA), 0.8 pmol FAM-labelled forward primer (GAGTCCCTCAAGTCCTTCCAGCA) and re-
verse primer (GCCCAAACTCACGGTCGGT) and 0.5 U AmpliTaq DNA polymerase (Applied
Biosystems). Cycling conditions were: 90 sec at 94°C, 35 × (30 sec at 94°C; 30 sec at 65°C; 90 sec
at 72°C) and 10 min at 72°C. After the PCR, for each sample, 1 μl of PCR product was mixed
with 9 μL of HiDi Formamide (Applied Biosystems) and 0.03 μl l MegaBACE ET900-R Size stan-
dards (GE Healthcare) and denatured at 95°C for 5 min. Samples were then run on an ABI3730
sequencer and analysed using GeneMapper v5.2- 3730XL software (Applied Biosystem).
Sensitivity of CAG assay was determined by mixing at different ratio KCL034 (clinical grade
wild-type hESC line) and KCL027 (HD-hESC line) genomic DNA, each diluted exactly to 50 ng/ml
(S1 Fig).
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Results
3.1. Characterization of HD-hESC lines
The purpose of pre-implantation genetic diagnosis (PGD) is to identify and exclude embryos
that carry the familial mutation. Such embryos are never destined for use in treatment and are
routinely discarded as soon as an affected status is diagnosed. If the patients decide to donate
these embryos to research, they give consent at the time of treatment. In our center we identify
HD specific mutation-carrying embryos by haplotyping using polymorphic markers flanking
and intragenic to theHTT gene on chromosome 4p16.3. Primers designed for 15 microsatellite
markers enable testing for inheritance of the at-risk HD allele. Three HD-hESC lines, KCL027,
KCL028 and KCL036, were derived in our center from embryos carrying HD-specific mutation
from two donor couples. One couple had eight affected embryos from which two lines,
KCL027 and KCL028, were derived and the other donor couple had one affected embryo, from
which KCL036 was derived [24].
All three lines were assessed for a number of parameters that are part of standard hESC
lines characterization [26, 31]. The identity of the cell lines was confirmed by genotyping; am-
plification of polymorphic microsatellite markers was carried out, giving a unique fingerprint
for each cell line (Fig 1A). The data confirmed that KCL027 and KCL028 are clonal related and
are both unrelated to KCL036. The presence of pluripotency markers in all three lines was
demonstrated by immunostaining using a panel of antibodies against transcription factors
NANOG and OCT4 and cell surface antigens TRA-1-60 and TRA-1-81. The HD-hESC colo-
nies were also positive for alkaline phosphatase (AP) activity using a commercially available kit
(Fig 1B). They had a typical morphology of normal healthy hESC colonies (Fig 1C). As the first
line test for genomic stability, we used array Comparative Genomic Hybridization (aCGH) as
described previously [25]. aCGH is an oligonucleotide platform with 60,000 probes that can de-
tect regions of imbalance down to approximately 25kb [32]. No genetic imbalance was detected
during extended periods of culture (data not shown).
3.2. HD-hESC-derived cardiomyocytes have a stable number of CAG
repeats
Next, we asked whether directed differentiation into cardiomyocytes would result in a change
in the number of CAG repeats. We differentiated the HD-hESCs in a monolayer following a di-
rected differentiation protocol [27]. All three differentiated HD-hESC lines presented beating
cardiomyocytes (Fig 2A). Using qPCR, we confirmed that 30 days after the start of differentia-
tion, expression of pluripotency-associated genes NANOG and OCT3/4 had diminished in all
three hESC lines, whereas the expression of cardiac-associated gene TNNT2 increased.HTT ex-
pression remained similar between undifferentiated hESCs and the cultures containing hESC-
derived cardiomyocytes (Fig 2B). The CAG repeat number of all three HD-hESC lines in affect-
ed and non-affected alleles remained stable throughout differentiation (Fig 2C). We then ex-
tended culture of differentiated cardiomyocytes for an additional 30 days and showed that the
number of CAG repeats in cells derived from two lines, KCL027 and KCL036, still remained
unchanged (Fig 2C). To our knowledge, this is the first demonstration of differentiation of
HD-mutation-carrying human pluripotent stem cells, either hESC or human induced pluripo-
tent stem cells (hiPSC), into cardiomyocytes, and assessment of the effect on the number of the
CAG repeats.
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Fig 1. HD-hESC lines characterization. (A) Genotyping: Microsatellite markers specific for chromosomes
13, 18, 21, X and Y were amplified. The allele sizes in bp for markers on chromosomes 13, 18, and 21 are
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3.3. Number of CAG repeats remains stable in multiple in vivo
differentiated tissues
Since CAG stability might differ from one tissue to another, we allowed the hESC to differenti-
ate spontaneously in vivo in order to mimic more closely a physiological environment. Differ-
ent techniques of generating teratomas, encapsulated tumors with tissue derivatives of all three
germ layers, have previously been described [33–35]. We injected cells embedded in Matrigel
from each of three HD-hESC lines (KCL027, KCL028 and KCL036) subcutaneously into
immunocompromized NOD-SCID mice (total n = 9 mice) and harvested them 10 weeks later.
Animals homozygous for the SCID mutation have impaired T and B cell lymphocyte develop-
ment, whereas the NOD background additionally results in deficient natural killer cell func-
tion. Teratomas in all lines consisted of tissue derivatives from all three germ layers (Fig 3A).
All tumors contained glandular epithelium, immature neural epithelium, immature
listed in the table. (B) Pluripotency markers: alkaline phosphatase (AP) activity, TRA-1–60, TRA-1–81,
OCT4, and Nanog were detected in undifferentiated cells of all three hESC lines. (C) HD-hESC colonies have
a typical morphology of normal hESC colonies.
doi:10.1371/journal.pone.0126860.g001
Fig 2. All three HD-hESC lines have stable number of CAG repeats upon directed cardiomyocyte
differentiation in vitro. (A) Beating cardiomyocytes were present in all three HD hESC lines examined in 2
independent rounds of differentiation. (B) Upon differentiation into cardiomyocytes for 30 days, expression of
the pluripotency markersNANOG andOCT4 is nearly undetectable, whereas the cardiomyocyte marker
TNNT2was increased. There is no change inHTT expression. Data are given by normalised
mean ± standard error of the mean (n = 3); statistical significance was calculated by an unpaired
homoscedastic one-tailed Student's t-test. NS, p 0.5 (non-significant); *p = 0.01–0.05 (significant);
***p 0.05 (extremely significant). (C) Top: Analysis of CAG repeats in undifferentiated KCL027 cells at the
start of differentiation [day 0] and 60-day after. Bottom: Number of CAG repeats in allele carrying HDmutation
has not increased after 30–60 days differentiation into cardiomyocytes.
doi:10.1371/journal.pone.0126860.g002
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mesenchyme, cartilage and endothelium. In addition, KCL027 and KCL028 teratomas con-
tained pigmented epithelium and arachnoidal tissue. We assessed the number of CAG repeats
in DNA isolated from sections of FFPE teratoma tissue samples. We found no increase in the
number of CAG repeats in the mutated allele in any of the lines examined (Fig 3B). However,
Fig 3. All three HD-hESC lines have stable number of CAG repeats upon spontaneous in vivo
differentiation. (A) Differentiation into the three germ layers in vivo: Teratomas were encapsulated and did
not invade surrounding tissue. Sections are counterstained with hematoxylin and eosin and specific stains
are either light blue (Alcian blue) or brown (all immunohistochemistry). Germ layer markers: Alcian blue—and
periodic acid–Schiff (PAS)-stained cartilage and desmin for mesoderm, neuron-specific β-III tubulin and glial
fibrillary acidic protein (GFAP) for ectoderm, GATA4 and α- fetoprotein for endoderm. (B) Number of CAG
repeats in allele carrying HDmutation did not increase during 10-week teratoma formation.
doi:10.1371/journal.pone.0126860.g003
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we detected a slight decrease in the number of CAG repeats in both the WT and HD allele of
line KCL027. Such short truncations have been reported previously [36, 37]. Taken together
the data suggest that the CAG repeat length remains the same following two different differen-
tiation techniques. To understand the molecular mechanisms of cardiac pathology in HD pa-
tients, HD-hESC and-hiPSC with a moderate increase in the number of CAG repeats may not
be the best in vitro cellular model.
Discussion
To complement HD in vivomodels, HD in vitromodels have been developed from mouse, rat
and human cells. These are in general immortalized cell lines with a genome-integrating viral
delivery system carrying a mutated HTT exon 1, expression of which is driven by an exogenous
promoter. These cell lines recapitulated some of the hallmarks features of HD, notably an in-
creased cell death and the formation of aggregates. Similar phenotypes have also been found in
primary cell models. However, it is not until recently that stem cells have been used to model
HD (Table 1).
Since the first disease-specific hESC line was derived from patients undergoing PGD for cys-
tic fibrosis [38], more than 20 HD-hESC lines have been derived worldwide. However, only a
few of them have been thoroughly characterized or used as research tools. Two HD-hESC lines
carrying 37 and 51 CAG repeats were indistinguishable morphologically from normal control
cell lines in the undifferentiated state and during differentiation into forebrain neurons. How-
ever, neural differentiation induced instability of CAG repeats and lines were gaining five to six
CAG repeats upon differentiation [39]. The expression of those genes that are deregulated in
HD remained unperturbed throughout differentiation. The only phenotype observed was an el-
evated glutamate-evoked response in neurons differentiated from an HD-hESC line with 51
CAG repeats [40]. A marked increase in the number of CAG repeats from 46 to 70 upon differ-
entiation into astroglial precursors was found in one HD-hESC line derived in our laboratory
[41]. On the other hand, two other groups reported that 40–48 CAG repeats were stable in five
undifferentiated and differentiated HD-hESCs [42, 43]. A later study involving these five HD-
hESC lines reported a down-regulation of theHTT gene itself in HD neural cells and dysregula-
tion of three genes, of which two, CHCHD2 and TRIM4, were also dysregulated in blood cells
from the HD patient [44]. In contrast, we could not detect any change in the levels ofHTT
gene expression in the cell exposed to our cardiac differentiation protocol (Fig 2B), indicating
that this phenomenon might be either cell line-related or specific to HD neurons but not to
other cell types. We also found that the number of CAG repeats was stable in cells that under-
went undirected in vivo differentiation, and those that underwent directed in vitro differentia-
tion towards a cardiac lineage. Taking together the reports from different groups to date, it
seems that some lines are prone to CAG expansion in vitro and others are not. Molecular
mechanisms behind these differences are still unknown. Although cell culture conditions
might play a role, genetic background of each individual line is likely to be more important. It
would be interesting to see how unstable CAG repeats in cell lines correlate with anticipation
in the families that donated the embryos. However, confidentiality surrounding human em-
bryo donation makes such comparison problematic.
Reprogramming of somatic cells into iPSC, discovered by Takahashi and Yamanaka [45],
could circumvent these issues. Derivation of HD-iPSC lines will enable comparison of disease-
in-the-dish phenotypes with clinical findings in somatic cell donors and affected members of
their families, leading to a better understanding of the role of genetic background and molecu-
lar mechanisms in development of HD-associated symptoms. The HD iPSC consortium re-
cently published findings showing that the positive correlation between the sizes of CAG
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repeats and the severity of symptoms observed in HD patients could also be observed in vitro
in HD-iPSC derived neurons [46]. A significant increase in lysosomal activity both during self-
renewal and in iPSC-derived neurons has been noted in the iPSC lines derived from two homo-
zygotes carrying 42/44 and 39/42 CAG repeats and one heterozygote carrying 17/45 CAG re-
peats [47]. The number of CAG repeats remained stable during the extended period of culture.
Another HD-iPSC line with 72 CAG repeats did not show any phenotype when cultured in
vitro or differentiated into neural precursors. However, when either subjected to oxidative
stress [48], proteasome inhibitor or engrafted into neonatal brains for 33 weeks, the HD-iPSCs
exhibited signs of HD pathology [49]. Elevated caspase activity in HD-iPSCs was also detected
in derived neurons of HD-iSPC line with 72 repeats [50].
The CAG-repeat expansion associated phenotypes already reported in transgenic models of
HD are the result of exogenous mutation, whereas phenotypes in HD-hESC and HD-iPSC
would be caused by endogenous mutation, more closely modeling in vivo disease. Our data
Table 1. Pluripotent stem cell in vitromodels of HD.
Cell line Species
origin
Cell type CAG repeat
size
Phenotype Reference
Mouse Neural stem cells 140/140;
HTT KO
Impaired motility, increased ROS,
dysregulated cholesterol
[51]
HD-iPS1 Human iPSC 72 [50, 52]
HdhCAG Mouse ESC 7, 77 and
150
Large CAG repeat sizes increase
neurogenesis
[53]
KCL005, KCL008 Human ESC 46 Increase in CAG repeats upon
differentiation into astroglial
precursors
[41]
KCL012, KCL013, KCL027,
KCL028, KCL036
Human ESC 42, 46 No phenotype reported [24, 25]
R6/1 Mouse ESC 127 CAG expansion, impaired DNA
repair, apoptosis
[54]
Mouse ESC 20, 50, 91,
111 and
HTT KO
Dysregulation of 73 genes [55]
TrES1 Monkey Pluripotent SC generated by the
fusion of transgenic HD monkey
skin ﬁbroblast and a wild-type
monkey oocyte
84 Presence of aggregates [56]
rHD-ESC Monkey ESC [57]
Human ESC with exogenous exon1
expression?
Insoluble HTT aggregates and
neurodegeneration
[58]
SI-186, SI-187 Human ESC 37 and 51 Increase in CAG repeats upon
neural differentiation; elevated
glutamate-evoked responses
[39, 40]
SI-187, SIVF017, SIVF018,
SIVF020, Huez2.3, VUB05
Human ESC 40–51 Downregulation of HTT,
dysregulation of CHCHD2, TRIM4,
and PKIB
[42–44]
HD-iPShom 4F-1, HD-iPShom 4F-
2, HD-iPShom 4F-3, HD-iPShom
3F-1, HD-iPShom 3F-2, HD-iPShet
3F-1
Human iPSC 42/44, 39/
42, 45
Increase in lysosomal activity [47]
HD60n, HD60i.3, HD60i.4,
HD109i.1, HD180n, HD180i.5,
HD180i6, HD180i7
Human iPSC 60, 109, 180 Disease-associated changes in
electrophysiology, metabolism, cell
adhesion, and apoptosis
[46]
Human iPSC 72 Deregulated expression of oxidative
stress proteins; aggregates
[48, 49]
doi:10.1371/journal.pone.0126860.t001
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further highlight the need to generate HD-iPSCs with a wider range of repeats and to correlate
the repeat instability in different tissue types with the medical history of donors and affected
members of their families.
Supporting Information
S1 Fig. The assay that we were using to detect abnormal number of CAG repeats in one
HTT allele could detect the mutation present in 1 μl of DNA from HD-hESC line KCL027
at concentration 50 ng/ml mixed with 39 μl of normal wild-type hESC line KCL034 of the
identical concentration, which would equal 1 out of 40 cells (2.5%).
(EPS)
S1 Table. Sense and Antisense primers of target genes used for hESC-derived cardiomyo-
cytes characterization.
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S2 Table. Housekeeping genes designed and synthesized by PrimerDesign Ltd used for
hESC-derived cardiomyocyte characterisation amplicon context. The primer sequences are
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